RVXCF (RVXCF) Stock Price & Analysis
RVXCF (RVXCF) rose 2.43% to USD 0.07 as of September 8, 2026 at 22:19 UTC, according to Nexqual real-time market data.
RVXCF last closed at USD 0.07; the session ranged USD 0.07–0.07 on volume of 500 shares. Market capitalization is $24.69M, with a 52-week range of USD 0.05–0.1 (PNK). Source: Nexqual, September 8, 2026 at 22:19 UTC.
Key Statistics (as of September 8, 2026 at 22:19 UTC)
| Price | USD 0.07 |
|---|---|
| Change | ▲ 2.43% (up) |
| Previous Close | USD 0.07 |
| Open | USD 0.07 |
| Day Range | USD 0.07 – 0.07 |
| 52-Week Range | USD 0.05 – 0.1 |
| Volume | 500 shares |
| Market Cap | $24.69M |
| Exchange | PNK |
Technical Analysis (RVXCF)
Nexqual's technical model rates RVXCF "STRONG SELL" based on 0 bullish and 5 bearish signals across 126 daily candles, as of September 8, 2026 at 22:19 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 45.71 (neutral) |
| vs SMA50 | Below (USD 0.07) |
| MACD | -0 (negative) |
Analyst Ratings (RVXCF)
Wall Street analysts rate RVXCF "None", per Nexqual as of September 8, 2026 at 22:19 UTC.
| Consensus Rating | None |
|---|
Earnings (RVXCF)
| Next Earnings Date | 2026-11-12 |
|---|
Source: Nexqual, September 8, 2026 at 22:19 UTC.
Financials & Fundamentals (RVXCF)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.04 |
| Total Cash | $80,000 |
| Total Debt | $91.45M |
| Free Cash Flow | $-4.24M |
Source: Nexqual, September 8, 2026 at 22:19 UTC.
Financial Health Score (RVXCF)
Nexqual rates RVXCF's overall financial health "Weak" across five dimensions, as of September 8, 2026 at 22:19 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $80K cash vs $91M debt |
| Cash Flow | Weak — Operating cash flow -$4M |
| Efficiency | Mixed — No data |
Ownership (RVXCF)
| Insider Ownership | +26.36% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 344.29M |
| Float | 251.22M |
Source: Nexqual, September 8, 2026 at 22:19 UTC.
Leadership (RVXCF)
RVXCF is led by Donald J. McCaffrey, Co-Founder, Chairman, President, CEO & Secretary, per Nexqual as of September 8, 2026 at 22:19 UTC.
| Co-Founder, Chairman, President, CEO & Secretary | Donald J. McCaffrey |
|---|---|
| Chief Financial Officer | Aaron Bradley Cann C.A., CPA, CBV |
| Chief Scientific Officer | Ewelina Kulikowski |
| Senior Vice President of Clinical Development | Michael Sweeney (age 64) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RVX.TO | RESVERLOGIX CORP. | CAD 0.1 | ▼ 5% |
| ZHCLF | Zenith Cap Corp. | USD 0 | ▲ 0% |
| SRBCF | Sirona Biochem Corp. | USD 0.01 | ▲ 0% |
| BIOAF | BIOASIS TECHNOLOGIES INC | USD 0 | ▲ 0% |
| SEOVF | SERNOVA BIOTHERAPEUTICS INC. | USD 0.1 | ▲ 25% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 22:19 UTC. This page is informational and not investment advice.